In patients with inflammatory bowel disease, neither biologics nor small molecule targeted therapies increase the risk for major adverse cardiac events, according to the largest study to address this question. Biologics were associated with a reduced risk for both major adverse cardiac events (MACE) and venous thromboembolism (VTE) relative to no biologics. Small molecule therapies, such as Janus kinase (JAK) inhibitors, were associated with a neutral effect. “Hopefully these data comfort us,” said investigator Miguel Regueiro, MD, the chair of the Digestive Disease & Surgery Institute at Cleveland Clinic, in Ohio. Dr. Regueiro also expressed hope these data might change…
Author: Abhay Panchal
The article on Healio discusses the new clinical guideline published by the American College of Gastroenterology (ACG) in the American Journal of Gastroenterology for the management of alcohol-associated liver disease (ALD). Key points from the guideline include: Avoidance of Alcohol Consumption: The guideline emphasizes that individuals with underlying obesity or chronic hepatitis C and B virus infection should avoid alcohol consumption. Additionally, those who have undergone or have a history of gastric bypass surgery should avoid heavy alcohol use. Screening and Treatment Recommendations: It recommends screening adults with suspected unhealthy alcohol use using tools like the Alcohol Use Disorders Identification…
The platform is a comprehensive biorepository containing over 150,000 samples collected from more than 10,000 patients, with over five years of clinical follow-up. It is designed to address unmet medical needs in liver disease, gastroenterology, and immune-mediated inflammatory conditions. The TARGET-NASH registry, a part of this platform, has alone gathered over 80,000 biospecimen samples. The platform focuses on diseases with high unmet medical needs and emerging therapies, particularly in areas like liver disease, metabolic dysfunction-associated steatohepatitis (MASH), and immune-mediated inflammatory conditions in dermatology and gastroenterology. The collected bio samples, including serum, whole blood, plasma, and skin tape strips, are obtained…
The evidence from various studies is mixed but general consensus is that AI devices can enhance adenoma detection rates (ADR) during colonoscopy, benefiting endoscopists at all levels of experience. Key Points: Clinical Trials vs. Real-World Results: While randomized clinical trials worldwide show an increase in ADR with AI use during colonoscopy, real-world results are varied. Some studies indicate improvement, while others do not. This discrepancy may be due to differences in study designs and implementation methods. Impact on Surveillance and Procedure Quality: AI use in colonoscopy has led to an increase in the proportion of patients requiring intensive surveillance, potentially…
A trio of studies presented at the 2023 annual meeting of the American College of Gastroenterology add support for the role of single-use duodenoscopes in endoscopic retrograde cholangiopancreatography. High Overall Success Rates in Meta-Analysis A systematic literature review revealed that single-use duodenoscopes are associated with a high success rate and promising safety profile in performing endoscopic retrograde cholangiopancreatography procedures (abstract P3717). Data from the 634 patients included in the meta-analysis showed an adjusted pooled procedural completion rate of 94%, which was statistically significant and higher than the American Society for Gastrointestinal Endoscopy threshold of 90% (P<0.001). Of note, there were…
Patients with inflammatory bowel disease are at increased risk for respiratory syncytial virus infection, according to new research presented at the 2023 annual meeting of the American College of Gastroenterology. Although patients with IBD are at an increased risk for developing respiratory infections, research has been limited on RSV in this setting, according to the researchers, led by Ryan A. Smith, MD, a gastroenterology fellow at the University of Wisconsin–Madison. He and his co-investigators wanted to evaluate whether patients with IBD are at an increased risk for RSV infection because that information can assist in informing appropriate vaccination strategies now…
AnX Robotica has announced the FDA clearance of NaviCam ProScan™, a groundbreaking AI-assisted reading tool for small bowel video capsule endoscopy. This clearance, achieved through the rigorous De Novo Submission Process, makes ProScan the first AI-assisted reading tool designed to aid in reviewing small bowel capsule endoscopy images for adult patients suspected of small bowel bleeding. ProScan leverages advanced AI technology to enhance the field of gastroenterology, enabling physicians to efficiently care for their patients. Dr. Cristiano Spada, a gastroenterology expert, praised this development as a significant advancement in small bowel capsule endoscopy, especially for patients with suspected gastrointestinal bleeding.…
EndoSound Inc., a medical technology company, has received 510(k) clearance from the FDA for its EndoSound Vision System® (EVS), a novel Endoscopic Ultrasound (EUS) device. This clearance, following the FDA’s Breakthrough Device designation in July 2021, marks a significant advancement in patient care. The EVS attaches to upper gastrointestinal endoscopes and integrates easily into existing endoscopy centers, making EUS more accessible and economical. It aims to shift the site of care to more efficient settings like ambulatory surgery centers (ASCs), preferred by patients, providers, and payers. The technology is recognized for its patient safety, cost reduction, and increased accessibility to…
HCP Live covers significant developments in the field of gastroenterology during December 2023. Key highlights include: American Gastroenterological Association (AGA) Guidelines: The AGA released two important guidelines in December. The first set of guidelines focuses on the use of biomarkers in managing Crohn’s Disease (CD), offering 11 conditional recommendations based on evidence and expert consensus. These guidelines emphasize the role of serum and fecal biomarkers as surrogates for endoscopic disease activity in CD. The second guideline pertains to the management of pouchitis and inflammatory pouch disorders, marking the first comprehensive evidence-based guideline in this area. Qazi Corner’s Fourth Installment: This…
Watch this amazing recap of The Scope Forward Show 2023 (Season 3). Risks in GI. Non-invasive testing. Breaking rules. Having a backup plan. Stool detection app. Reimbursement for AI. Self driving endoscopy. Lead, don’t get left behind. Endoscopy robots as part of the team. Value of data in GI. Precision medicine. Unconventional ideas. Thank YOU guests for the amazing work you do, for being so candid, and for making The Scope Forward Show one of the most influential podcasts in gastroenterology.